美国 · SEC FORM 4
Camp4 Therapeutics Corp
CAMP · Nasdaq · CIK 0001736730 · Healthcare · Biotechnology
内部人信号
5 qualifying P purchase groups
当前 180 天评分窗口
11 同一窗口内观察到的 Form 4 交易行
6 sales · 0 期权、代扣税、授予、赠与或其他交易行
为什么没有活跃信号？
评分构成
活跃窗口内没有合资格买入，因此不计算分数。缺失的输入不会被当作零分或看空信号。
为什么没有分数？
- 没有合资格公开市场买入可提供聚集度、规模、角色、近期性或确信度输入。
- 卖出及其他 Form 4 活动继续作为背景显示，不会形成负分。
卖出和其他 Form 4 活动会单独显示，不会形成负面买入信号。没有买入不会被评分为看空。
内部人活动时间轴
申报人轨道展示最近 180 天。符号形状区分交易类型；卖出仅作为背景。
—
买方广度与集中度
Roles in the peak window: Chief Executive Officer, Chief Financial Officer, Chief Medical Officer, Director. Concentration uses priced qualifying P lines only and does not change the saved score.
信号历史
Scores are archived only when the company qualifies for a published US buy-signal snapshot. 最近一次合资格买入: 2026-08-31 · Gold Kelly.
近期 Form 4 活动
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
市场背景补充近期价格表现与风险信息，不影响内部人信号。
价格表现
- 1M
- +5.3%
- 3M
- -6.5%
- 6M
- -10.5%
- 12M
- —
波动率与流动性
- 波动率
- 111.2%
- Beta
- —
- 平均每日成交额
- —
估值
- 市值
- —
- P/E
- —
基本面
- 利润率
- —
- ROE
- -168.5%
- 细分行业
- Biotechnology
市场数据
价格数据截至：2026-10-04 · 价格来源：OpenBB/yfinance · 来自 SEC 申报文件：ROE · 财年截止日：2025-12-31 · Status: PASS
空头余额
空头余额是券商向 FINRA 申报的外部背景数据，不影响内部人信号。
- 空头股数
- 1,459,951
- 上期报告
- 992,712
- 日均成交量
- 284,354
- 回补天数
- 5.1
FINRA 结算日：2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数，每月两个结算日之后约一周公布；不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-08-31 | Gold Kelly | 买入 (P) | Common Stock | 10,000 | USD 3.96 | USD 39,600 | SEC 申报 ↗ |
| 2026-08-03 | Young Richard A | 买入 (P) | Common Stock | 16,378 | USD 1.65 | USD 27,024 | SEC 申报 ↗ |
| 2026-08-03 | Maricich Yuri | 买入 (P) | Common Stock | 6,551 | USD 1.65 | USD 10,809 | SEC 申报 ↗ |
| 2026-08-03 | Mandel-Brehm Josh | 买入 (P) | Common Stock | 6,551 | USD 1.65 | USD 10,809 | SEC 申报 ↗ |
| 2026-08-03 | Gold Kelly | 买入 (P) | Common Stock | 6,551 | USD 1.65 | USD 10,809 | SEC 申报 ↗ |
| 2025-09-11 | 5AM Opportunities II (GP), LLC; 5AM Opportunities II, L.P.; 5AM Partners VI, LLC; 5AM Partners VII, LLC; 5AM Ventures VI, L.P.; 5AM Ventures VII, L.P.; PARMAR KUSH | 买入 (P) | Common Stock | 2,941,176 | USD 1.53 | USD 4,499,999 | SEC 申报 ↗ |
| 2025-09-11 | Young Richard A | 买入 (P) | Common Stock | 15,151 | USD 1.65 | USD 24,999 | SEC 申报 ↗ |
| 2025-09-11 | Nashat Amir | 买入 (P) | Common Stock | 1,307,189 | USD 1.53 | USD 1,999,999 | SEC 申报 ↗ |
| 2025-09-11 | Maricich Yuri | 买入 (P) | Common Stock | 6,060 | USD 1.65 | USD 9,999 | SEC 申报 ↗ |
| 2025-09-11 | Mandel-Brehm Josh | 买入 (P) | Common Stock | 6,060 | USD 1.65 | USD 9,999 | SEC 申报 ↗ |
| 2025-09-11 | Gold Kelly | 买入 (P) | Common Stock | 6,060 | USD 1.65 | USD 9,999 | SEC 申报 ↗ |
| 2025-09-11 | Chee Brian; Polaris Entrepreneurs' Fund VII, L.P.; Polaris Management Co. VII, L.L.C.; Polaris Partners GP X, L.L.C.; Polaris Partners VII, L.P.; Polaris Partners X, L.P.; SCHULMAN AMY W | 买入 (P) | Common Stock | 1,307,189 | USD 1.53 | USD 1,999,999 | SEC 申报 ↗ |
| 2024-10-15 | Chee Brian; Polaris Entrepreneurs' Fund VII, L.P.; Polaris Management Co. VII, L.L.C.; Polaris Partners GP X, L.L.C.; Polaris Partners VII, L.P.; Polaris Partners X, L.P.; SCHULMAN AMY W | 买入 (P) | Common Stock | 909,090 | USD 11.00 | USD 9,999,990 | SEC 申报 ↗ |
| 2024-10-15 | Northpond Ventures GP, LLC; Northpond Ventures II GP, LLC; Northpond Ventures II, LP; Northpond Ventures III GP, LLC; Northpond Ventures III, LP; Northpond Ventures, LP; Rubin Michael P. | 买入 (P) | Common Stock | 763,636 | USD 11.00 | USD 8,399,996 | SEC 申报 ↗ |
| 2024-10-15 | Enavate Sciences GP, LLC; Everest Aggregator, LP | 买入 (P) | Common Stock | 1,363,636 | USD 11.00 | USD 14,999,996 | SEC 申报 ↗ |
Form 4 申报证据
11 transaction lines in the latest 365-day window; 54 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-08-31 | Gold Kelly | 买入 (P) | Common Stock | 10,000 | USD 3.96 | USD 39,600 | SEC 申报 ↗ |
| 2026-08-27 | Schwab Andrew J. | 卖出 (S) | Common Stock | 400,000 | USD 4.04 | USD 1,616,000 | SEC 申报 ↗ |
| 2026-08-24 | Schwab Andrew J. | 卖出 (S) | Common Stock | 10 | USD 4.50 | USD 45 | SEC 申报 ↗ |
展开近期 Form 4 证据 (11 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-08-31 | Gold Kelly | 买入 (P) | Common Stock | 10,000 | USD 3.96 | USD 39,600 | SEC 申报 ↗ |
| 2026-08-27 | Schwab Andrew J. | 卖出 (S) | Common Stock | 400,000 | USD 4.04 | USD 1,616,000 | SEC 申报 ↗ |
| 2026-08-24 | Schwab Andrew J. | 卖出 (S) | Common Stock | 10 | USD 4.50 | USD 45 | SEC 申报 ↗ |
| 2026-08-21 | Schwab Andrew J. | 卖出 (S) | Common Stock | 32,018 | USD 4.50 | USD 144,081 | SEC 申报 ↗ |
| 2026-08-20 | Schwab Andrew J. | 卖出 (S) | Common Stock | 114,700 | USD 4.54 | USD 520,738 | SEC 申报 ↗ |
| 2026-08-19 | Schwab Andrew J. | 卖出 (S) | Common Stock | 45,147 | USD 4.76 | USD 214,900 | SEC 申报 ↗ |
| 2026-08-19 | Tardiff Daniel | 卖出 (S) | Common Stock | 1,738 | USD 4.76 | USD 8,273 | SEC 申报 ↗ |
| 2026-08-03 | Young Richard A | 买入 (P) | Common Stock | 16,378 | USD 1.65 | USD 27,024 | SEC 申报 ↗ |
| 2026-08-03 | Maricich Yuri | 买入 (P) | Common Stock | 6,551 | USD 1.65 | USD 10,809 | SEC 申报 ↗ |
| 2026-08-03 | Mandel-Brehm Josh | 买入 (P) | Common Stock | 6,551 | USD 1.65 | USD 10,809 | SEC 申报 ↗ |
| 2026-08-03 | Gold Kelly | 买入 (P) | Common Stock | 6,551 | USD 1.65 | USD 10,809 | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-18 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | CAMP |
| CIK | 0001736730 |
| 行业 | Healthcare |
| 细分行业 | Biotechnology Yahoo Finance |
| SEC SIC | 2834 Pharmaceutical Preparations |
| 交易所 | Nasdaq |
数据覆盖
| 本地 Form 4 历史 | 54 transaction lines from 2024-10-15 to 2026-08-31 23 P purchase lines · 6 S sale lines · 25 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.